SLC16A1 and non-small cell lung carcinoma: Sukeda et al. [47], Eilertsen et al. [69] and Martins et al. [59] observed that elevated MCT1 protein levels were seen in PDAC, in NSCLC and in CRC patients (respectively) who showed increased OS [47,59,69], PFS [47] and disease-specific survival [69] rates.